bluebird bio, Inc. (BLUE)

Market Cap	177.92M
Revenue (ttm)	21.73M
Net Income (ttm)	-91.17M
Shares Out	192.74M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,459,392
Open	0.975
Previous Close	0.975
Day's Range	0.920 - 0.980
52-Week Range	0.850 - 5.530
Beta	0.86
Analysts	Hold
Price Target	5.41 (+486.07%)
Earnings Date	Aug 6, 2024

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and effic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2013
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: BLUE

Financial Performance

In 2022, bluebird bio's revenue was $3.60 million, a decrease of -1.77% compared to the previous year's $3.66 million. Losses were -$266.58 million, -67.47% less than in 2021.

Analyst Forecast

According to 10 analysts, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is $5.41, which is an increase of 486.07% from the latest price.

Price Target

$5.41

(486.07% upside)

Analyst Consensus: Hold